Rapport Therapeutics (NASDAQ:RAPP) CFO Troy A. Ignelzi Acquires 9,900 Shares of Stock

Posted by Anthony Miller on Mar 14th, 2025

Rapport Therapeutics (NASDAQ:RAPP – Get Free Report) CFO Troy A. Ignelzi bought 9,900 shares of Rapport Therapeutics stock in a transaction that occurred on Wednesday, March 12th. The shares were acquired at an average price of $10.10 per share, for a total transaction of $99,990.00. Following the completion of the transaction, the chief financial officer now directly owns 9,900 shares of the company’s stock, valued at $99,990. This trade represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Rapport Therapeutics Price Performance

RAPP opened at $10.02 on Friday. Rapport Therapeutics has a 1 year low of $6.43 and a 1 year high of $29.74. The firm has a 50 day moving average price of $13.72 and a 200 day moving average price of $18.82.

Institutional Investors Weigh In On Rapport Therapeutics

Large investors have recently modified their holdings of the stock. Deutsche Bank AG acquired a new stake in shares of Rapport Therapeutics during the fourth quarter worth approximately $41,000. Crestline Management LP acquired a new stake in Rapport Therapeutics in the 4th quarter valued at about $488,000. Virtus ETF Advisers LLC acquired a new stake in shares of Rapport Therapeutics during the 4th quarter valued at $66,000. Price T Rowe Associates Inc. MD raised its holdings in shares of Rapport Therapeutics by 9.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,143,384 shares of the company’s stock valued at $20,285,000 after acquiring an additional 95,976 shares during the period. Finally, TRV GP V LLC acquired a new position in Rapport Therapeutics in the 4th quarter worth approximately $126,579,000.

About Rapport Therapeutics

(Get Free Report)

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.